Euroapi Company Header Euroapi Company Header

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu
    [{"orgOrder":0,"company":"Exavir Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Exavir Therapeutics Announces Preclinical Data Demonstrating Complete Elimination of HIV From Human Cells With LNP-Delivered Tat-targeted CRISPR-Cas9","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"IND Enabling","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"November 2021","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling"},{"orgOrder":0,"company":"Exavir Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Exavir Therapeutics Announces Publication of Preclinical Data for Ultra-long-acting Dolutegravir Prodrug XVIR-120","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2022","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical"},{"orgOrder":0,"company":"Exavir Therapeutics","sponsor":"National Institute of Allergy and Infectious Diseases","pharmaFlowCategory":"D","amount":"$3.0 million","upfrontCash":"Undisclosed","newsHeadline":"Exavir Therapeutics Receives $3M Award from NIH \/ NIAID to Advance Ultra-Long-Acting Integrase Inhibitor XVIR-110","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"IND Enabling","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2023","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling"},{"orgOrder":0,"company":"Exavir Therapeutics","sponsor":"ViiV Healthcare","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Exavir Enters Settlement and License Agreement for HIV Compounds with ViiV Healthcare","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2024","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical"}]

    Find Clinical Drug Pipeline Developments & Deals by Exavir Therapeutics

    Menu

    Exavir Therapeutics

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Loading...

    All Data

    Previous
    Next
    Filters Filter
    ×
    FILTER:
    filter Company
      filter Sponsor
        filter Country
          filter Therapeutic Area
            filter Study Phase

              Active Filter(s):

              refreshFilters
              refreshReset Filter
              refresh Reset Filter
              price-trend All Developments

              Companies By Therapeutic Area

              Development Status

              Exavir Therapeutics

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Exavir Enters Settlement and License Agreement for HIV Compounds with ViiV Healthcare

              Details:

              Through the licensing agreement, the company will focus on advancing XVIR-110, which is currently being evaluated in early-stage clinical trials for the treatment of HIV infections.

              Lead Product(s): XVIR-110

              Therapeutic Area: Infections and Infectious Diseases Product Name: XVIR-110

              Highest Development Status: Preclinical Product Type: Small molecule

              Partner/Sponsor/Collaborator: ViiV Healthcare

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Licensing Agreement May 22, 2024

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Exavir Therapeutics

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Exavir Therapeutics Receives $3M Award from NIH / NIAID to Advance Ultra-Long-Acting Integrase Inhibitor XVIR-110

              Details:

              The proceeds will be used to advance XVIR-110, an ultra-long-acting HIV integrase inhibitor with a preclinical profile that suggests best-in-class potential for HIV pre-exposure prophylaxis, and for HIV treatment as the cornerstone of a next-generation multi-drug regimen.

              Lead Product(s): XVIR-110

              Therapeutic Area: Infections and Infectious Diseases Product Name: XVIR-110

              Highest Development Status: IND Enabling Product Type: Small molecule

              Partner/Sponsor/Collaborator: National Institute of Allergy and Infectious Diseases

              Deal Size: $3.0 million Upfront Cash: Undisclosed

              Deal Type: Funding August 22, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Exavir Therapeutics

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Exavir Therapeutics Announces Publication of Preclinical Data for Ultra-long-acting Dolutegravir Prodrug XVIR-120

              Details:

              XVIR-120, a novel nano-formulated prodrug of dolutegravir, across preliminary rodent and non-human primate studies which demonstrate that injections were well tolerated and support ultra-long-acting dosing intervals.

              Lead Product(s): Dolutegravir Prodrug

              Therapeutic Area: Infections and Infectious Diseases Product Name: XVIR-120

              Highest Development Status: Preclinical Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable June 09, 2022

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Exavir Therapeutics

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Exavir Therapeutics Announces Preclinical Data Demonstrating Complete Elimination of HIV From Human Cells With LNP-Delivered Tat-targeted CRISPR-Cas9

              Details:

              INSTI - ULA, a once yearly ultra-long-acting (ULA) injectable agent targeting HIV integrase small molecules, currently in IND-enabling studies.

              Lead Product(s): INSTI - ULA

              Therapeutic Area: Infections and Infectious Diseases Product Name: INSTI - ULA

              Highest Development Status: IND Enabling Product Type: Cell and Gene therapy

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable November 10, 2021

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity
              Farmhispania Group, a leading European CDMO in HPAPI Technologies & High Potency Fermentation.
              One Pharma aims to be one of the leading generic companies in Europe.
              Post Enquiry
              POST ENQUIRY